Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s Why Arena Pharmaceuticals, Inc. (ARNA) Shares Are Lower

Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) have fallen $0.23 per share, or 15.5%, on Tuesday after the company executed a spot secondary of 60 million shares at $1.15 a piece. Leerink and Citi are the book runners of the offering, with which Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) intends to use the net proceeds to fund the clinical and preclinical development of drug candidates, as well as for general corporate purposes, including working capital and costs associated with manufacturing services, and for capital expenditures.

Although the offering gives Arena more resources, some Wall Street bulls aren’t too happy. Also on Tuesday, Edward Tenthoff of Piper Jaffray trimmed his price target on Arena to $2.5 from the previous $3.5 per share, citing the dilution caused by the offering. Tenthoff maintains his ‘Overweight’ recommendation, however.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

11 institutions (out of the 742 top funds that we track) reported long positions of $22.93 million of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and accounted for 6.60% of the float on December 31, versus 9 funds and $32.61 million on September 30. In terms of noteworthy individual activity, Jim Simons‘ Renaissance Technologies raised its stake by 9% in Q4 to 7.52 million shares at the end of December.

The Bottom Line

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares are down due to a secondary. For more reading, check out ‘11 Most Commonly Used Illegal Drugs‘.

Follow Arena Pharmaceuticals Inc (NASDAQ:ARNA)
Trade (NASDAQ:ARNA) Now!

Disclosure:None

stocks, analysis, market, numbers, business, ticker, trade, money, price, investment, index, chart

crystal51/Shutterstock.com